The Effects of Pharmaceutical Excipients on Gastrointestinal Tract Metabolic Enzymes and Transporters-an Update
- PMID: 27184579
- DOI: 10.1208/s12248-016-9928-8
The Effects of Pharmaceutical Excipients on Gastrointestinal Tract Metabolic Enzymes and Transporters-an Update
Abstract
Accumulating evidence from the last decade has shown that many pharmaceutical excipients are not pharmacologically inert but instead have effects on metabolic enzymes and/or drug transporters. Hence, the absorption, distribution, metabolism, and elimination (ADME) of active pharmaceutical ingredients (APIs) may be altered due to the modulation of their metabolism and transport by excipients. The impact of excipients is a potential concern for Biopharmaceutics Classification System (BCS)-based biowaivers, particularly as the BCS-based biowaivers have been extended to class 3 drugs in certain dosage forms. The presence of different excipients or varying amounts of excipients between formulations may result in bio-inequivalence. The excipient impact may lead to significant variations in clinical outcomes as well. The aim of this paper is to review the recent findings of excipient effects on gastrointestinal (GI) absorption, focusing on their interactions with the metabolic enzymes and transporters in the GI tract. A wide range of commonly used excipients such as binders, diluents, fillers, solvents, and surfactants are discussed here. We summarized the reported effects of those excipients on GI tract phase I and phase II enzymes, uptake and efflux transporters, and relevant clinical significance. This information can enhance our understanding of excipient influence on drug absorption and is useful in designing pharmacokinetic studies and evaluating the resultant data.
Keywords: absorption; metabolic enzyme; pharmaceutical excipient; pharmacokinetics; transporter.
Comment on
-
Improvement of the oral drug absorption of topotecan through the inhibition of intestinal xenobiotic efflux transporter, breast cancer resistance protein, by excipients.Drug Metab Dispos. 2007 Jul;35(7):1142-8. doi: 10.1124/dmd.106.014217. Epub 2007 Apr 19. Drug Metab Dispos. 2007. PMID: 17446265
-
Effects of monoglycerides on P-glycoprotein: modulation of the activity and expression in Caco-2 cell monolayers.Mol Pharm. 2008 Sep-Oct;5(5):863-75. doi: 10.1021/mp800050q. Epub 2008 Jul 24. Mol Pharm. 2008. PMID: 18651749
-
Nonionic surfactants are strong inhibitors of cytochrome P450 3A biotransformation activity in vitro and in vivo.Eur J Pharm Sci. 2009 Mar 2;36(4-5):401-11. doi: 10.1016/j.ejps.2008.11.002. Epub 2008 Nov 8. Eur J Pharm Sci. 2009. PMID: 19041719
-
Effects of commonly used excipients on the expression of CYP3A4 in colon and liver cells.Pharm Res. 2010 Aug;27(8):1703-12. doi: 10.1007/s11095-010-0170-2. Epub 2010 May 26. Pharm Res. 2010. PMID: 20503067 Free PMC article.
-
Commonly used nonionic surfactants interact differently with the human efflux transporters ABCB1 (p-glycoprotein) and ABCC2 (MRP2).Eur J Pharm Biopharm. 2010 Oct;76(2):260-8. doi: 10.1016/j.ejpb.2010.06.008. Epub 2010 Jun 19. Eur J Pharm Biopharm. 2010. PMID: 20600890
-
The effect of polyoxyethylene polymers on the transport of ranitidine in Caco-2 cell monolayers.Int J Pharm. 2011 May 16;409(1-2):164-8. doi: 10.1016/j.ijpharm.2011.02.059. Epub 2011 Mar 4. Int J Pharm. 2011. PMID: 21382460
-
Mediation of in vitro cytochrome p450 activity by common pharmaceutical excipients.Mol Pharm. 2013 Jul 1;10(7):2739-48. doi: 10.1021/mp400175n. Epub 2013 Jun 10. Mol Pharm. 2013. PMID: 23701529
-
Enhanced intestinal absorption of etoposide by self-microemulsifying drug delivery systems: roles of P-glycoprotein and cytochrome P450 3A inhibition.Eur J Pharm Sci. 2013 Nov 20;50(3-4):429-39. doi: 10.1016/j.ejps.2013.08.016. Epub 2013 Aug 25. Eur J Pharm Sci. 2013. PMID: 23981337
-
Enhanced Permeability of Etoposide across Everted Sacs of Rat Small Intestine by Vitamin E-TPGS.Iran J Pharm Res. 2013 Winter;12(Suppl):37-46. Iran J Pharm Res. 2013. PMID: 24250670 Free PMC article.
-
Inhibition mechanism of P-glycoprotein mediated efflux by mPEG-PLA and influence of PLA chain length on P-glycoprotein inhibition activity.Mol Pharm. 2014 Jan 6;11(1):71-80. doi: 10.1021/mp4004223. Epub 2013 Nov 22. Mol Pharm. 2014. PMID: 24256068
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
